Effects of fixed-dose indapamide/perindopril combination on arterial function in patients with hypertension and chronic kidney disease: Key results of the CAMERTON program

Aim. To study the effects of fixed-dose indapamide/perindopril combination on endothelial function and arterial stiffness in patients with uncontrolled stage 1-2 hypertension (HTN) and chronic kidney disease (CKD). Material and methods. Total of 100 patients with uncured or uncontrolled with ≥3 months antihypertensive therapy HTN and CKD G3 (67% females, mean age 59,1±12,5 years) were included in the study. Each patient took indapamide/perindopril combination in accordance with 1 of 3 existing regimes (depending on doses) for 3 months. Primary aim was to assess the effects of indapamide/perindopril combination on endothelial function and parameters of arterial stiffness after 12 weeks of treatment (assessment by AngioScan diagnostic complex). Secondary aims were achievement of target blood pressure (BP) after 4 and 12 weeks of therapy and assessment of glomerular filtration rate (GFR) and the albumin-to-creatinine ratio (ACR) changes after 12 weeks. Results. Initially, there was an increase in arterial stiffness parameters in all patients, and during treatment decrease was observed: central systolic BP (SBP) from 120±10,1 to 112,9±6,3 mm Hg, median augmentation index from 10,9% to 4,6%, stiffness index from 8,1±2,4 to 7,1±0,9, vascular age decreased by 9,6% (р<0,001 for trend). Significant improvement of endothelial function was observed regardless of diabetes presence: occlusion index increased from 1,5±0,3 to 1,7±0,5, median phase shift — from-4,6 to-2,4 ms (p<0,001 for trend). After 12 weeks of therapy, the absolute decrease of SBP was 37,8 mm Hg, diastolic BP — 13,3 mm Hg (p<0,01). After 4 weeks, 27% of patients reached target BP, by the end of the study — 90%. A decrease in the median ACR from 16,3 to 15,0 mg/g, GFR increase from 50,2±7,6 to 53,6±8,7 ml/min/1,73 m2 were observed (p<0,01 for trend). Conclusion. Therapy with a fixed-dose indapamide/perindopril combination in patients with uncontrolled stage 1-2 HTN and G3 CKD leads to a significant improvement in arterial stiffness, endothelial and renal function, and achievement of target BP in 90% of patients. © 2019, Silicea-Poligraf. All rights reserved.

Номер выпуска
  • 1 The Peoples’ Friendship University of Russia, Moscow, Russian Federation
  • 2 Research Center Hospital, Irkutsk, Russian Federation
Ключевые слова
Arterial stiffness; Chronic kidney disease; Endothelial function; Fixed-dose combination; Hypertension; Indapamide/perindopril
Дата создания
Дата изменения
Постоянная ссылка

Другие записи